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Abstract 
Prostate cancer is the second leading cause of cancer deaths in men in the United 
States (Siegel 2019).  This honors thesis quantified the expression of Endothelial Protein 
C Receptor (EPCR) in the serum of patients with varying stages of prostate cancer and 
determined its expression in the prostate cancer cell line, PC3. EPCR and its ligand, protein 
C, play an important role in the anticoagulation cascade that prevents thrombosis from 
occurring at the sight of a vascular injury (Esmon 1992). Previous research regarding tumor 
metastasis and the coagulation cascade in ovarian cancer has shown that there is also an 
association between the expression of EPCR and the metastasis of cancer cells, as cells that 
expressed EPCR were more prone to survive, divide, and eventually become metastatic 
(Ducros et al. 2012). The expression of EPCR on breast tumor cells promotes their 
metastasis by activating the cytoprotective mechanisms of Activated Protein C (APC) and 
allowing them to invade the circulatory system and avoid immune detection by the host 
organism (Griffin 2012). Researchers have investigated the use of EPCR concentration in 
patient serum samples and in ovarian cancer cell lines as a potential biomarker for ovarian 
cancer. These researchers found that there was a correlation between the stage of ovarian 
cancer and the concentration of EPCR found in the patient serum (Ducros et al. 2012).  
Since previous research has shown that EPCR is expressed in breast cancer and 
ovarian cancer cells, this study investigated if EPCR is also present in prostate cancer cells. 
The expression of EPCR in serum samples may be used to confirm the diagnosis of prostate 
cancer and may also be used to determine the stage of prostate cancer. EPCR expression 
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in the prostate cancer cell line, PC3, and the concentration of EPCR in serum from patients 
with prostate cancer were determined. An immunoprecipitation and western blot was 
performed on PC3 cell media and cell lysates to determine if EPCR is expressed by prostate 
cancer cells. Bands appeared in all lanes of the western blot at 49 kDa indicating EPCR 
was expressed in the media and lysates of PC-3 cells. An ELISA was performed to quantify 
the concentration of EPCR in prostate cancer patient serum samples. There was a 
significant differences between the means of EPCR concentrations in patients with varying 
Gleason Scores of prostate cancer (p<0.001), with patients with prostate cancer having 
elevated concentrations of EPCR compared to controls.   
We conclude that EPCR is expressed by prostate tumor cells and that patients with 
prostate cancer Gleason grades 4-8 have statistically elevated concentrations of serum 
EPCR when compared to the levels of EPCR expression in control serum samples.  This 
indicates that the expression of EPCR in serum of patients can be used as a biomarker for 
prostate cancer. The concentration of EPCR in serum samples can indicate the severity or 
score of the prostate cancer the patient has.  
 
Introduction 
The Coagulation Process and the Role of Thrombin 
It is common for blood vessels to be damaged during an injury and for this damage 
to lead to bleeding at the site of the wound. In order to maintain hemostasis at the site of 
the vascular injury, both coagulation and anticoagulation cascades are utilized at 
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appropriate times to ensure the cessation of bleeding from the blood vessel and the 
prevention of clot formation within the blood vessel known as thrombosis. The coagulation 
process begins when a platelet plug is formed at the site of the vascular injury. Following 
the formation of a platelet plug, the procoagulant enzyme, thrombin, is eventually 
generated from its precursor prothrombin. Thrombin then converts fibrinogen to fibrin. 
Fibrin adds stability to the platelet plug and forms what is known as a secondary plug at 
the location of the vascular damage (Palta 2014). This process is responsible for the 
cessation of bleeding at the site of the vascular injury.  
 
Activated Protein C and Endothelial Protein C Receptors 
During the coagulation process, the levels of the plasma protein, prothrombin, are 
nearly 100 times greater than the amount of thrombin that is needed for clot formation. 
This excess prothrombin leads to the overproduction of thrombin and causes massive 
clotting, known as thrombosis, which is detrimental to the organism (Esmon 1989). This 
excess thrombin binds to the endothelial cell surface protein, thrombomodulin (TM), which 
with the coreceptor, EPCR, activates the anticoagulant enzyme protein C to activated 
protein C (APC) (Griffin 2012). The process by which Protein C is activated is shown in 
Figure 1 below.  
To regulate the procoagulant effect of thrombin, the anticoagulant enzyme, APC, 
and its cofactor protein S then inhibit the two cofactors, Va and VIIIa, that are needed for 
the formation of thrombin (Figure 1). When bound to APC, Protein S causes a 
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conformational change that positions the active site of APC closer to the cell membrane so 
that it is in the optimal position to inhibit the Va and VIIIa cofactors of prothrombin (Griffin 
2012).  
Endothelial Protein C Receptor (EPCR) enhances the rate of activation of APC by 
thrombin bound to TM (Ruf 2014).  As indicated by their name, EPCR’s are integral 
membrane proteins found on endothelial cells lining the blood vessels (Fukudome 1994).  
Once Protein C binds to EPCR, it is oriented in a manner that better exposes it to the 
thrombin-TM complex for activation (Figure 1).  Once activated, Protein C inhibits the 
procoagulant effect of the thrombin molecules that normally promote the formation of 
fibrin as described above. Protein C inhibits this to avoid thrombosis within the vessel 
(Griffin 2012).  
APC also performs many other cytoprotective activities on cells through 
interactions with EPCR. The interaction between APC and EPCR has been linked with 
anti-apoptotic, anti-inflammatory, and cell barrier protection responses in cells to protect 
them from many harmful agents (Griffin 2012).  After the APC is activated, it remains 
active until it is inactivated by Protein C Inhibitor (PCI) or α1 anti-trypsin. However, 
Protein C is inactivated very slowly with a half-life of 15 minutes (Esmon 1989).  
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Figure 1: Protein C Pathway The binding of thrombin to the transmembrane protein thrombomodulin and 
the binding of Protein C to EPCR causes the activation of Protein C to proceed at an enhanced rate. Once 
activated, APC, along with its cofactor Protein S, inhibits the cofactors Va and VIIIa of prothrombin that are 
necessary to form more thrombin. (https://basicmedicalkey.com/bleeding-and-thrombotic-disorders/) 
 
Tumor Growth and Metastasis  
Cancer can develop in any cell that has mutations that result in uncontrolled cell 
division. This may produce tumors that can either be malignant or benign.  Benign tumors 
do not spread into neighboring tissue or other parts of the body. Malignant tumors are 
capable of spreading to nearby tissue, lymph nodes, and other parts of the organism.  
Metastasis is the process by which cancerous tumor cells spread to multiple 
locations within an organism from an initial tumor growth site. For a tumor to become 
malignant and metastasize, several conditions must be met. Tumor cells first break free 
from their intercellular connections with other tumor cells and interact with the 
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extracellular matrix (ECM) of neighboring tissues. Tumor cells secrete enzymes that 
degrade the ECM. Following this degradation, the tumor cells are able to propel themselves 
through the ECM and become invasive. As the tumor continues to grow and invade 
surrounding tissue, it may eventually invade the vascular network of the host and enter the 
circulatory or lymphatic systems where they may make their way to other locations in the 
organism. To metastasize, the tumor cells must also avoid the host’s immune cells in the 
vascular network. To invade a secondary tissue, they must also adhere to the endothelial 
cells of the vasculature before attempting to invade tissue at a secondary location (Abbas 
2017).  
Tumors require oxygen and nutrients to continue growing, therefore, they cannot 
continue growing past 1-2mm without their own vascular network. Angiogenesis is 
triggered in growing tumors by an increase in angiogenesis promoters and a decrease in 
angiogenesis inhibitors. Tumors undergoing angiogenesis form their own vascular 
networks that stem from preexisting capillaries. Access to these new vessels allows the 
tumor cells to enter the bloodstream and metastasize throughout the organism (Abbas 
2017).  
 
Correlation between EPCR and Tumor Cell Metastasis 
There has been recent evidence proving that the coagulation system plays a role in 
tumor cell metastasis and cancer progression. Earliest research found that when 
anticoagulants were used to treat cancer patients, the anticoagulants limited the growth and 
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metastasis of the tumor cells. This treatment method was developed from studies that 
revealed that even minute amounts of thrombin enhance the rate of cancer metastasis (Sluis 
2010). This sparked an interest in the association of cancer progression and the APC 
anticoagulation pathway.  
EPCR expression on vascular endothelial cells prevents the adhesion and migration 
of tumor cells within the vessels, which suggests that the anticoagulation cascade prevents 
tumor cell growth and metastasis (Sluis 2010). However, EPCR expression is found to be 
upregulated on breast cancer cells. This expression of EPCR on cancer cells allows them 
to activate protein C and its inflammatory and anti-apoptotic effects. These signals 
transduced by ECPR-bound APC in cancer cells has been shown to promote cancer 
metastasis and angiogenesis (Sluis 2010).  
 Other research focused on the growth of breast cancer in mammary glands. This 
research performed by Ruf and Schaffner (2014) found that there was a direct correlation 
between tumor cells that expressed EPCR and breast cancer metastasis. As stated 
previously, APC alone has no prometastatic effects on tumor cells. In fact, this research 
found that Activated Protein C and EPCR expressed in vascular endothelial cells reduce 
the metastatic effects of the thrombin produced by the interaction with tumor cells and 
epithelial cells. This research focused on the expression of EPCR in cancer stem cells. They 
found that the most aggressive breast cancer cell lines could be identified by their 
expression of EPCR. The cancer cells that expressed EPCR were more capable of growth 
and survival. This research also suggested that these cancer cells may use the expression 
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of EPCR to trigger the host’s innate immune system to regulate the differentiation and 
retention of stem cells, allowing for the overproduction of tumor cells (Ruf 2014).  
 Ducros et al. (2012), who investigated the expression of EPCR in ovarian cancer, 
indicated that EPCR could be used as a possible biomarker for the onset of ovarian, breast, 
and lung cancer.These researchers found that the concentration of EPCR in the plasma 
samples of patients with ovarian cancer was significantly higher than in the plasma samples 
obtained from healthy patients (Ducros et al. 2012). The expression of EPCR in plasma 
was also found to be related to cell survival, invasion, and immune down regulation. This 
suggested that elevated levels of EPCR in plasma indicates the onset of ovarian cancer and 
can, therefore, be used as a potential biomarker (Ducros et al. 2012). While this research 
focused primarily on ovarian cancer, our study investigates the potential use of EPCR 
expression as a biomarker for prostate cancer.  
 
Prostate Cancer 
 Prostate cancer is the second leading cause of death by cancer in men (Seigel 2019). 
To determine if EPCR is expressed in prostate cancer cells, cells from the prostate cancer 
cell line PC3 were cultured in the lab. The cultured prostate cancer cells were then used for 
an immunoprecipitation, SDS-PAGE, and Western blot analysis to determine if the EPCR 
protein was present. Plasma samples collected from Carolinas Medical Center (Atrium 
Health Medical Facility) were used to perform ELISAs and quantify and compare the 
concentration of EPCR in patients with varying stages/grades of prostate cancer to control 
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serum (no prostate cancer). Due to the fact that there was a correlation between the 
expression of EPCR and the invasion and metastasis of breast cancer cells, it was predicted 
that EPCR would be found in both the PC3 cells and the serum samples of prostate cancer 
patients and that patients with prostate cancer would have elevated serum concentrations 
compared to controls.  
 
Materials and Methods 
Immunoprecipitation  
The PC3 cell line was used to determine if EPCR is expressed in prostate cancer 
cells. PC3 cells (ATCC) were cultured in DMEM media supplemented with L-glutamine, 
sodium pyruvate, and 10% Fetal Bovine Serum (Sigma Aldrich).  PC3 cells were 
maintained in T25 cell culture flasks with 5ml of media at 37ºC with 5% CO2. When cells 
were 80% confluent, media was replaced with serum free media for 12 hours. EPCR was 
then immunoprecipitated from 1ml of cell media and cell lysates from these cells. For the 
immunoprecipitation process, immunoprecipitation buffer (0.1 M Tris – HCl, 25 mM 
EDTA, 5 mM benzamidine, 5 mg/ml bovine serum albumin, 2.5% Triton X-100, 2.5% 
deoxycholate) was then added to the 1mL of media and cell lysis buffer (150 mM sodium 
chloride, 1.0% NP-40 (Triton X-100 can be substituted for NP-40),  50 mM Tris pH 8.0) 
was added to the cells remaining in the flask. Following 5 minutes of incubation with the 
cell lysis buffer, the cells were transferred to a tube and centrifuged to remove debris. 1mL 
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of the supernatant was transferred to a clean tube to which the immunoprecipitation buffer 
was then added.  
Sixty µl of α-mouse IgG-agarose (Sigma) was added to both the precipitated media 
and cell lysate for 20 minutes. This was then zip spun and the supernatant was removed. 
2µl of the EPCR-MAb (Sigma) was then added to the supernatant and it was allowed to 
shake overnight at room temperature. 60 µl of α-mouse-IgG-agarose was then added for 
one hour at 4ºC followed by centrifugation. The beads were then washed with 300µl TBS 
and 40µl of non-reduced SDS-PAGE sample buffer was added for 10 minutes at 90ºC. 
Finally, following centrifugation, the supernatant was removed and a 10% SDS-PAGE and 
Western was performed. 
 
SDS-PAGE and Western Blot 
A vertical polyacrylamide gel was used to separate the EPCR based on molecular 
weight. The gel was loaded with 20 l samples of both cell media and cell lysate along 
with a rainbow molecular weight ladder. The gel was run at 15 mA for 15’ and then at 30-
35 mA until the bands reached the bottom of the gel.  Following SDS-PAGE, a Western 
Blot was used to visualize the protein bands. The gel was transferred onto nitrocellulose at  
25 V for 1 hour. The gel was then removed and Coomassie stained to detect any remaining 
protein. The nitrocellulose was used for western blot probing and detection. The 
nitrocellulose was blocked with 3% milk in 1xTBS buffer for 30 minutes. It was then rinsed 
with TBS and the 1 g primary antibody EPCR-MAb in 1% milk was added and allowed 
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incubate at 4oC overnight. The nitrocellulose was then rinsed three times with TBS for five 
minutes. The secondary antibody α-mouse IgG-agarose was then added and allowed to 
rock for one to three hours. This was then rinsed with TBS twice for five minutes each time 
and was left in distilled water. Enhanced chemiluminescent (ECL) detection was 
performed to detect the protein present.  
 
Figure 2: Arrangement Order for Western Blot Transfer To transfer the protein from the gel to the 
nitrocellulose membrane, they were placed in a cassette with four sponges and four pieces of filter paper. 
They were arranged in the following order: two sponges, two pieces of filter paper, the gel, the nitrocellulose 
membrane, two pieces of filter paper, and two sponges. (https://www.clinisciences.com/it/read/western-blot-
516/western-blot-protocol-1727.html) 
ELISA 
 Serum samples were collected from patients with various grades of prostate cancer 
from Carolinas Medical Center, Charlotte, NC using an IRB approved protocol (Drs. 
Glasscock and Teigland). These samples were then de-identified by Dr. Glasscock to 
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maintain patient privacy.  These samples were stored in liquid nitrogen and at -20ºC up 
until 24 hours before the assay occurred. 24 hours before assaying the samples, the samples 
were stored at 2-8ºC. Serum samples were then centrifuged and diluted 1:2 before use. A 
Human EPCR PicoKine ELISA Kit (Boster) was then used to perform the assay. The serum 
samples were activated using solution A (1N HCl) and B (1.2N NaOH/ 0.5M HEPES). An 
EPCR standard was reconstituted to 316 pg/ml as directed by the instructions provided in 
the ELISA kit. The biotinylated anti-human EPCR antibody working dilution was then 
prepared by adding 10mL of antibody diluent buffer to the whole anti-human EPCR 
antibody. The avidin-biotin-peroxidases complex working solution was also prepared by 
adding 10mL of ABC dilution buffer to 130µL of the avidin-biotin-peroxidases complex.  
A plate coated with EPCR-Mab from mouse, was then prepared. 100µl of the 
standard curve was added to the plate in triplicate (0 ng/ml –800 ng/ml). 100µl of each 
activated serum sample and the control female serum sample were then added in triplicate. 
The plate was covered and placed in a 37ºC with 5% CO2 incubator for 30 minutes. The 
contents were then removed from the plate and 100µl of the biotinylated anti-human EPCR 
antibody working solution was added to each well. This was allowed to incubate for 60 
minutes at 37ºC, 5% CO2. Following incubation, the plate was washed three times with 
0.01M PBS. 100µl of ABC working solution was then added to each well and the plate was 
once again allowed to incubate for 30 minutes at 37ºC, 5% CO2. Following incubation, the 
plate was washed five times with 0.01M PBS. 90µL of the TMB color developing agent 
was then added to each well and the plate was left in the dark at 37ºC for 15-20 minutes 
Bonner 14 
 
until a color change from blue to yellow was observed as shown in Figure 3. The 
absorbance at 450nm was then read and the data was analyzed to determine the mean 
concentration +/- standard deviation of EPCR for each patient. Three ELISAs were 
performed.  
 
Figure 3: ELISA Plate Following TMB Color Developing Agent Color Change. Each sample and a control 
were plated in triplicate along with a standard curve. TMB Color Developing Agent was added and a color 
change was observed. Once plates turned the yellow color shown above, the OD absorbance of the plate was 
then ready to be read.  
 
Results 
SDS-PAGE and Western Blot  
The western blot perfromed presented bands in all five lanes as shown in Figure 4 
below.  Lane two contained 20µg/ml purified EPCR.  Both cell media and cell lystates 
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contained  a protein that co-migrated with the postitive control with a molecular weight of  
49kDa, the molecular weight of EPCR.  
 
Figure 4 EPCR expression in PC3 cells.  EPCR was immunoprecipitated from PC3 cell media and lysates 
and evaluated using Western blotting.  Lane one consists of the molecular weight ladder (kDa). Lane two 
contains purified EPCR, 20µg/ml. Lane three contains the sample from cell media collected in November 
2019. Lane four contains a sample of cell lysate also collected in November 2019. Lane five contains the 
sample from cell media collected in January 2020. Lane six contains a sample of cell lysate also collected in 
January 2020. 
 
ELISA 
Three ELISAs were done to determine the concentration of EPCR in the serum of 
patients with prostate cancer. A standard curve graph was constructed for each ELISA and 
used to determine the concentration of EPCR in each patient sample. Standard Curve 1 
(Figure 5A) was used to determine the concentration of EPCR in patients 1-26 and control 
serum 1. Standard Curve 2 (Figure 5B) was used to determine the concentration of EPCR 
in patients 27-51 and control serum 2. Standard Curve 3 (Figure 5C) was used to determine 
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Figure 5 Standard Curves for ELISAs One, Two, and Three Standard curves were constructed for each ELISA 
performed and were used to determine the concentration of EPCR in each patients serum sample along with the control 
samples.  
the concentration of EPCR in patients 52-76 and control serum 3. For each sample, the 
triplicate absorbance readings were averaged together.  
 
 
 
  
Each of the concentrations were then multiplied by their dilution factor to find the 
final concentration of EPCR in each patient’s serum sample. Each patient’s Gleason Score 
for prostate cancer was then identified. All patients had a Gleason score ranging from 5-8. 
Average EPCR concentration for each score was calculated for ELISAs one, two and three 
and are shown in Table 1 below.  
GLEASON SCORE 
 5 6 7 8 
ELISA 1  373.69+/- 171.21  615.38+/-34.67 780.5+/-44.24 814.88+/- 84.57 
ELISA 2  410+/- 118.46 659.45+/-28.07 766+/- 30.18 870+/- 0  
ELISA 3  440.75+/- 198.61 600.45+/- 56.19 772.86+/- 41.16 840+/- 24.15 
Table 1: Average EPCR Concentration by Gleason Score Averages of EPCR concentration (g/ml) were calculated for 
patients with a prostate cancer Gleason score of 5, 6, 7, and 8. These averages were determined for each ELISA.  
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An ANOVA test was performed on each ELISA to determine if there was a 
difference in the means of EPCR concentration for each Gleason score and the control 
concentration. An ANOVA on ELISA 1 rejected the null hypothesis that there would be 
no significant difference in the means of EPCR concentrations in patients with differing 
Gleason scores of prostate cancer since the F calculated (23.64) was greater than the critical 
value (3.049) (P<0.0001), indicating that there is a statistical difference in the means of 
EPCR concentrations in patients with differing Gleason scores. A Tukey test was then 
performed on ELISA 1 and showed that patients with a Gleason score of 5 had a statistically 
lower EPCR concentration that those with scores of 6, 7 and 8 (p<0.01). There was also a 
statistical difference in EPCR concentration between patients with a score of 6 and a score 
of 8 (p<0.05).  Individual patient EPCR concentrations for ELISA 1 patients 1 through 26 
can be found in Appendix A below.  
An ANOVA on ELISA 2 rejected the null hypothesis that there would be no 
significant difference in the means of EPCR concentrations in patients with differing 
Gleason scores of prostate cancer since the F calculated (77.08) was greater than the critical 
value (2.895) (P<0.0001), indicating that there is a statistical difference in the means of 
EPCR concentrations in patients with differing Gleason scores. A Tukey test was then 
performed on ELISA 2 and showed that patients with a Gleason score of 5 had a statistically 
lower EPCR concentration that those with scores of 6, 7 and 8 (p<0.01). There was also a 
statistical difference in EPCR concentration between patients with a score of 6 and a score 
Bonner 18 
 
of 8 (p<0.01). Individual patient EPCR concentrations for ELISA 2 patients 27 through 51 
can be found in Appendix B below. 
An ANOVA on ELISA 3 also rejected the null hypothesis that there would be no 
significant difference in the means of EPCR concentrations in patients with differing 
Gleason scores of prostate cancer since the F calculated (33.19) was greater than the critical 
value (2.895) (P<0.0001), indicating that there is a statistical difference in the means of 
EPCR concentrations in patients with differing Gleason scores. A Tukey test was then 
performed on ELISA 3 and showed that patients with a Gleason score of 5 had a statistically 
lower EPCR concentration that those with scores of 7 and 8 (p<0.01). There was also a 
statistical difference in EPCR concentration between patients with a score of 6 and a score 
of 8 (p<0.01). Individual patient EPCR concentrations for ELISA 3 patients 52 through 76 
can be found in Appendix C below. 
For each ELISA performed, all concentrations of EPCR in patients with prostate 
cancer were significantly higher than the concentration of EPCR in the control serum 
(p<0.01). Figure 6 represents all paitents compared in each of the ELISAs. All patients 
with prostate cancer also had concentrations of EPCR that were greater than the 100 µg/ml 
basline (Figure 6).  
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Figure 6: EPCR Concentrations for All Patients with Prostate Cancer All concentrations of EPCR for patients with 
prostate cancer were greater than the baseline concentration of 100µg/ml and all were significantly greater than the EPCR 
concentration in the control serum.  
 
 
 
Discussion 
The western blot performed with both cell lysates and cell media indicated that 
EPCR is expressed by prostate cancer cells. As indicated by previous research on breast 
cancer cell lines, the most aggressive breast cancer cell lines expressed EPCR at levels that 
made the cancer cells identifiable when compared with normal cells (Ruf 2014). The results 
presented by this western blot also correspond with those of Menschikowski et. al (2011) 
who found that EPCR expression is upregulated at both the mRNA and protein levels in 
PC-3 Cell lines. These prostate cancer cells expressing EPCR may be more capable of 
growth and survival as indicated by the work of Ruf and Schafer, and may utilize the hosts 
immune system to control the differentiation of stem cells into tumor cells (2014). 
I reject the null hypothesis that there will be now statistical difference in EPCR 
concentrations in patients with varying prostate cancer Gleason scores. Individual 
ANOVAs for EPCR concentration in patients with varying Gleason scores of prostate 
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cancers indicated that there was a statistical difference in EPCR concentration in patients 
with prostate cancer (p<0.01). The Tukey tests performed also indicated that there were 
statistically significant differences in EPCR concentrations between patients with a score 
of 5 and those with a score of 6,7, and 8 (p<0.01) and a statistical difference in EPCR 
concentration between those with a score 6 and a score of 8 (p<0.01). As previous research 
has indicated, EPCR has potential as a biomarker for  ovarian cancer as they found that the 
concentration of EPCR in the plasma samples of patients with ovarian cancer was 
significantly higher than in the plasma samples obtained from healthy patients (Ducros et 
al. 2012).  The increase in EPCR expression may be linked to the EPCR mediated survival 
and anti-apoptotic signaling pathways which allows APC to act as a pro-carcinogenic agent 
in patients with high Gleason scores (Menschikowski et al. 2011). These results indicate 
that the expression of EPCR in the serum samples of patients can be used as a biomarker 
to indicate the onset of prostate cancer and potentially the grade of prostate cancer that the 
patient may possess.  
  These results support the hypothesis that patients with prostate cancer will have a 
higher level of EPCR expression in their serum than the female control serum. Those with 
Gleason scores of 6, 7, 8 have statistically higher levels of EPCR than those with Gleason 
scores of 4 and 5. This indicates that the expression of EPCR correlates with the stage of 
prostate cancer the patient has. This data can be used in medical facilities to determine or 
diagnose patients with prostate cancer.   
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 The expression of EPCR in prostate cancer cells and in patient serum samples can 
be further studied to determine the average level of EPCR expression for each Gleason 
score of prostate cancer. This information can be used by medical facilities who wish to 
determine the stage of cancer the patient has based on the concentration of EPCR found in 
their serum.  
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Appendix A 
ELISA 1 EPCR Concentration (µg/ml) 
Control1 102 +/- 4.33 
P1 772.5 +/- 60.62 
P2 600 +/- 85.18 
P3 195 +/- 53.21 
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P4 267 +/- 56.29 
P5 82.5 +/- 138.8 
P6 600 +/- 27.04 
P7 697.5 +/- 7.5 
P8 606 +/- 33.82 
P9 810 +/- 45.83 
P10 532.5 +/- 33.82 
P11 660 +/- 26.34 
P12 786 +/- 73.61 
P13 882 +/- 27.04 
P14 727.5 +/- 37.5 
P15 603 +/- 27.04 
P16 757.5 +/- 30.31 
P17 402 +/- 73.87 
P18 660 +/- 27.04 
P19 822 +/- 116.3 
P20 486 +/- 43.3 
P21 795 +/- 18.87 
P22 892.5 +/- 30.31 
P23 507 +/- 49.94 
P24 558 +/- 28.39 
P25 636 +/- 15.15 
P26 517.5 +/- 57.28 
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Appendix B 
ELISA 2 EPCR Concentration (µg/ml) 
Control2 30 +/- 0.37 
P27 685 +/- 178.49 
P28 685 +/- 123.93 
P29 635 +/- 151.74 
P30 750 +/- 136.97 
P31 310 +/- 313.74 
P32 510 +/- 27.54 
P33 768 +/- 92.38 
P34 770 +/- 94.12 
P35 790 +/- 107.16 
P36 655 +/- 54.85 
P37 665 +/- 98.66 
P38 640 +/- 206.54 
P39 670 +/- 149.75 
P40 770 +/- 60 
P41 675 +/- 165.40 
P42 870 +/- 5.77 
P43 700 +/- 124.23 
P44  603.33 +/- 66.58 
P45 630 +/- 161.58 
P46 585 +/- 40 
P47 520 +/- 49.07 
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P48 660 +/- 40.10 
P49 790 +/- 84.12 
P50 654 +/- 61.71 
P51 790 +/- 86.75 
 
Appendix C 
ELISA 3 EPCR Concentration (µg/ml) 
Control3 95 +/- 5 
P52 575 +/- 25.98 
P53 655 +/- 33.29 
P54 540 +/- 11.55 
P55 660 +/- 33.29 
P56 680 +/- 47.70 
P57 545 +/- 25.98 
P58 800 +/- 92.60 
P59 850 +/- 17.32 
P60 585 +/- 32.79 
P61 715 +/- 20 
P62 540 +/- 15.28 
P63 765 +/- 55.68 
P64 665 +/- 44.44 
P65 820 +/- 42.52 
P66 845 +/- 25.98 
P67 535 +/- 17.56 
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P68 495 +/- 53.93 
P69 740 +/- 36.06 
P70 805 +/- 50.08 
P71 585 +/- 22.55 
P72 805 +/- 73.99 
P73 615 +/- 30.14 
P74 860 +/- 42.52 
P75 148 +/- 339.42 
P76 545 +/- 23.63 
 
 
 
 
